Quote | Synaptogenix Inc. (OTCMKTS:SNPX)
Last: | $1.56 |
---|---|
Change Percent: | 15.56% |
Open: | $1.35 |
Close: | $1.56 |
High: | $1.6 |
Low: | $1.27 |
Volume: | 38,601 |
Last Trade Date Time: | 05/18/2021 04:42:35 am |
News | Synaptogenix Inc. (OTCMKTS:SNPX)
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...
2024-05-20 11:54:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Synaptogenix (NASDAQ: SNPX ) just reported results for the first quarter of 2024. Synaptogenix reported earnings per share of -41 cents. The company did not report any...
Message Board Posts | Synaptogenix Inc. (OTCMKTS:SNPX)
Subject | By | Source | When |
---|---|---|---|
I agree in principal but unless NIH funds | runncoach | investorshub | 04/14/2023 6:55:44 PM |
I don't think Bryostatin is done. I | Battle Ready | investorshub | 04/14/2023 4:34:29 PM |
If Bryostatin is done for work and I | runncoach | investorshub | 04/14/2023 4:22:05 PM |
I had only kept 1000 shares of Petros, | Battle Ready | investorshub | 04/14/2023 4:19:14 PM |
Anyone that still has shares of petros from | runncoach | investorshub | 04/14/2023 4:10:24 PM |
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery PR Newswire Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways ...